Summary of Study ST002153

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001366. The data can be accessed directly via it's Project DOI: 10.21228/M85115 This work is supported by NIH grant, U2C- DK119886. See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files
Study IDST002153
Study TitleData from plasma metabolome analysis of APP-KI and Wild type mice treated with B. breve MCC1274
Study SummaryRecently, we showed that administration of B. breve MCC1274 reduced amyloid-beta production, inhibited microglial activation, and suppressed inflammatory responses in the brains of APP knock-in (AppNL-G-F) mice. To elucidate the mechanism of action of this probiotic strain in an Alzheimer's disease-like model, we orally fed 3-month-old mice with B. breve MCC1274 or saline for 4 months and comprehensively investigated metabolites in plasma using CE-FTMS and LC-TOFMS.
Institute
Morinaga milk industry CO., LTD.
DepartmentNext generation science institute
LaboratoryFrontier research section
Last NameOhno
First NameKazuya
Address1-83 5-Chome Higashihara, Zama-city, Kanagawa-Pref. Japan
Emailkazuya-oono443@morinagamilk.co.jp
Phone81462523067
Submit Date2022-04-18
Analysis Type DetailLC-MS
Release Date2022-10-03
Release Version1
Kazuya Ohno Kazuya Ohno
https://dx.doi.org/10.21228/M85115
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:TR002251
Treatment Summary:Three-month-old AppNL-G-F and wild type mice were randomly assigned to a vehicle group and a probiotic group. The vehicle group received saline, and the probiotic group received B. breve MCC1274 (1 × 10＾9 cfu/200 μl saline/mouse) orally 5 times a week for 4 months.
Treatment Compound:Bifidobacterium breve MCC1274
Treatment Route:oral administration
Treatment Dosevolume:1 × 10＾9 cfu/200 μl saline
Treatment Vehicle:saline
  logo